FDA Approves METHOTREXATE — Teva Pharmaceuticals USA, Inc.

# FDA Approves Teva Pharmaceuticals' Generic Methotrexate Oral Formulation Teva Pharmaceuticals USA, Inc. received FDA approval for its generic methotrexate sodium oral formulation (ANDA081099), expanding the company's presence in the competitive oncology and immunosuppressant market and enabling broader patient access to this widely-prescribed disease-modifying drug. The approval positions Teva to capture market share in the methotrexate segment, which serves multiple therapeutic areas including cancer treatment, rheumatoid arthritis, and autoimmune disorders